This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Professor Nicholas Barnes PhD

Professor Nicholas Barnes PhD


Professor Nicholas Barnes PhD FBPhS


University of Birmingham & Celentyx Ltd

Year elected:


Primary professional setting:


Professor Nicholas Barnes has been a member of the Faculty of the University of Birmingham Medical School since 1991 and holds the Chair in Neuropharmacology. He is Director of the Cellular and Molecular Neuropharmacology Research Group; the group’s principal research interest is 5-HT (5-hydroxytryptamine, serotonin). In addition, Professor Barnes is Chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Nomenclature Committee for Serotonin Receptors. He is also Editor-in-Chief, Board Editor and Associate Editor for the international journals Frontiers in Neuropharmacology, Neuropharmacology, and Frontiers in Neuroscience, respectively. In addition to his academic-related positions, Professor Barnes is the Principal Founder and CEO of Celentyx Ltd; a venture capital funded pharmaceutical research and development company with a therapeutic focus on treating disorders of the immune system and targeting cancer treatment with immuno-oncology strategies.